Nutarniq Corp is built on the clinical research of Dr. Evan Lewis who has developed and tested a unique type of omega-3 fats as targeted nutritional therapy to enhance neuromuscular function. Dr. Lewis has focused his research on providing a therapeutic solution to the most prevalent and pervasive neuromuscular disease facing the world, diabetes-induced nerve damage, diagnosed as diabetic neuropathy. Diabetes is a global pandemic that affects over 415 million people and is expected to increase 40% by 2040. Over 50% of all diabetics will develop diabetic neuropathy.
Dr. Evan Lewis PhD - CEO & Chief Scientist
Evan’s passion for nutritional science and human performance developed from his time training as an athlete on the Canadian Sailing Team. Evan completed his MSc at the University of Toronto, Faculty of Kinesiology where he investigated the hydration and energy requirements for Canadian Sailing Team athletes in preparation for the 2012 Olympics. He completed his PhD at the University of Toronto, Department of Nutritional Sciences, Faculty of Medicine where he investigated the effects of seal oil omega-3 supplementation on neuromuscular function in athletes. The positive results from this research lead to investigating seal oil as a therapy for diabetic neuropathy.
Dr. Roger Mahabir LLD (Hon)
Roger Mahabir is Chairman & CEO of Tracker Networks Inc
. He also serves as President of Technology Innovations Inc., and as Corporate Director for the Greater Toronto Airports Authority, which operates Toronto’s Pearson International Airport. He is a trained corporate director, having served on over 20 boards and advisory boards of NYSE, NASDAQ, TSX and Silicon Valley companies in the US, Canada and Europe. Roger is an active Angel investor, philanthropist, mentor to entrepreneurial students and executives.
Dr. Vera Bril MD FRCPC
Dr. Vera Bril is a Professor of Medicine (Neurology) at the University of Toronto, Director of Neurology at University Health Network and Mount Sinai Hospital
and the Krembil Family Chair in Neurology. Her research interests have centred on the diagnosis and evidence-based treatment of myasthenia gravis, inflammatory polyneuropathies, and diabetic sensorimotor polyneuropathy. Her work has helped set the standards for electrophysiological investigations in the definition and evaluation of the progression of chronic polyneuropathies.
Dr. Bruce Perkins MD MPH MRCPC
Dr. Perkins is a Professor of Medicine (Endocrinology & Metabolism) at the University of Toronto and a Clinician Scientist at the Leadership Sinai Centre for Diabetes
. His current research interests are diabetic neuropathy (nerve damage), diabetic kidney disease and strategies to help improve blood sugar control which include the development of the artificial pancreas.